9-ING-41 NEW
| Price | $45 | $64 | $101 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-20 |
Product Details
| Product Name: 9-ING-41 | CAS No.: 1034895-42-5 |
| Purity: 99.32% | Supply Ability: 10g |
| Release date: 2026/04/20 |
Product Introduction
Bioactivity
| Name | 9-ING-41 |
| Description | 9-ING-41 is a glycogen synthase kinase-3 inhibitor. |
| In vitro | 9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM[2]. |
| In vivo | In a mouse model of MCL, 9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 125 mg/mL (309.14 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | GSK-3β | GSK-3 | GSK3 | Glycogen synthase kinase-3 | Glycogen synthase kinase 3 | cycle | cell | Autophagy | arrest | Apoptosis | anticancer | activity | 9-ING-41 | 9ING41 | 9 ING 41 |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Ethyl linoleate | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Neuroprotective Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:2913223-17-1
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $33.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $75.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-13 | |
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2025-04-02 | ||
| $45.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY